Put companies on watchlist
Carl Zeiss Meditec AG
ISIN: DE0005313704
WKN: 531370
Curious about what AI knows about Carl Zeiss Meditec? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Carl Zeiss Meditec AG · ISIN: DE0005313704 · EQS - adhoc news (44 News)
Country: Germany · Primary market: Germany · EQS NID: 1237251
30 September 2021 04:20PM

Leadership Change in the Executive Board of Carl Zeiss Meditec AG


DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Personnel
Leadership Change in the Executive Board of Carl Zeiss Meditec AG

30-Sep-2021 / 16:20 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Leadership Change in the Executive Board of Carl Zeiss Meditec AG

Jena, September 30, 2021

The Supervisory Board of Carl Zeiss Meditec AG (ISIN: DE0005313704) has agreed on a change in the Executive Board of the company. Dr. Ludwin Monz, who has been Chief Executive Officer of the company since 2010, will turn over his position to Dr. Markus Weber, currently member of the Executive Board of Carl Zeiss AG, on December 31, 2021. The transition is happening on the best of terms and at Dr. Monz' own request.

Dr. Weber has more than 20 years of experience in various management and research and development functions within the ZEISS Group and, on the Executive Board of Carl Zeiss AG, is currently responsible for the Semiconductor Technology segment. Along with his new role as Chief Executive Officer of Carl Zeiss Meditec AG, Dr. Weber will remain on the board of Carl Zeiss AG, assuming the responsibilities of Dr. Monz on that board, who will leave the Executive Board of Carl Zeiss AG on December 31, 2021.

In the view of the Supervisory Board of Carl Zeiss Meditec AG, management continuity is assured via the internal succession. The other two members of the Executive Board, Justus Felix Wehmer and Jan Willem de Cler, will remain in their current positions.
 
 

Contact for investors and press
Sebastian Frericks
Head of Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.meditec@zeiss.com


30-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1237251

 
End of Announcement DGAP News Service

1237251  30-Sep-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1237251&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Carl Zeiss Meditec AG
Smart analysis and research tools can be found here.
MIC: XETR

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.